ANTIMICROBIAL STUDIES OF B. BURGDOR FERI

莱姆病是美国主要的媒介传播细菌疾病。 美国，可能还有全世界。这种疾病的病原体， 伯氏疏螺旋体由全球分布的硬蜱传播 硬蜱属的硬壳动物。除了急性形式的 在患病的情况下，慢性感染可能会持续多年。 莱姆病的早期和晚期表现可以与 存活螺旋体的数量很少。最有效的 抗菌药物、剂量、治疗路线和治疗时间尚未 为莱姆病建立的。尽管临床研究表明 如果出现以下情况，大多数患者对抗菌治疗的反应令人满意 在疾病的早期就开始了，这种情况的例外尤其发生。 当病人有神经受累时。然而，对 由于螺旋体潜伏，这种疾病的治疗是有问题的。 以及病情恶化和缓解的间歇性模式 未经治疗的感染的自然病史。 测定体外和体内抗菌剂的标准方法 对挑剔、生长缓慢的细菌的敏感性，如B。 还没有建立世代时间为10-20小时的Burgdorferi。 重要的是要有这些方法来识别 可有效治疗莱姆病的抗菌药 以及一种动物模型来研究各种治疗方案。 这项建议的具体目标是：一、制定标准方法 B。体外药敏试验。 勃格多费里。体外抗菌药物标准品的研究进展 药敏方案：A.确定伯氏杆菌对 新的以及一些常用的抗菌剂和 抗菌药物组合。B.比较B组的体外敏感性。 伯氏杆菌从不同地理区域分离到具有代表性的 抗菌剂。 二、体内抗菌剂检测标准方法的建立 实验感染仓鼠对伯氏杆菌的敏感性。 体内抗菌素标准方法的最新进展 药敏试验：A.测定B。 伯氏杆菌对体外具有良好活性的抗菌剂。胡麻B. 联合用药与单用抗菌药物的疗效比较 心理治疗。评估类固醇在抗菌治疗中的作用。D. 金黄地鼠抗菌治疗效果的实验比较 通过注射感染与通过扁虱叮咬感染。E.评估 抗菌预防对蚤传播的效果观察。 伯氏杆菌感染。

Lyme disease is the leading vector-borne bacterial disease in the United States and probably the world. The etiologic agent of this disease, Borrelia burgdorferi, is transmitted by the globally distributed ixodid ticks of the genus Ixodes. In addition to the acute form of the illness, a chronic infection may develop that can persist for years. The early and late manifestation of Lyme disease can be correlated with the presence of low numbers of viable spirochetes. The most effective antimicrobial, dosage, route and length of treatment have not been established for Lyme disease. Although clinical studies suggest that most patients respond satisfactorily to antimicrobial therapy if initiated early in the disease, exceptions to this occur particularly when patients have neurologic involvement. However, evaluation of the treatment of this disease is problematic due to the spirochetes latency and the intermittent pattern of exacerbations and remissions in the natural history of untreated infections. Standard methods for detemining the in vitro and in vivo antimicrobials susceptibility of fastidious, slow-growing bacteria, such as B. burgdorferi with a generation time of 10-20 hr have not been establdhed. It is important to have these methods available to identify antimicrobials that could be effective for the treatment of Lyme disease and an animal model to investigate various treatment protocols. The specific aims of this proposal are: I. Develop standard method for determination of in vitro antimicrobial susceptibility of B. burgdorferi. Following development of standard in vitro antimicrobial susceptibility protocol: A. Determine sensitivity of B. burgdorferi to new as well as some of the commonly used antimicrobials and antimicrobial combinations. B. Compare in vitro susceptibility of B. burgdorferi isolates from diverse geographical areas to representative antimicrobial agents. II. Develop standard method for determination of in vivo antimicrobial susceptibility of B. burgdorferi in experimentally infected hamsters. Following development of standard method for the in vivo antimicrobial susceptibility assay: A. Determine in vivo susceptibility of B. burgdorferi to antimicrobials that possess good in vitro activity. B. Compare efficacy of combined antimicrobial therapy with single agent therapy. C. Evaluate effect of steroids on antimicrobial therapy. D. Compare efficacy of antimicrobial therapy in hamsters experimentally infected by injection versus infection via tick bite. E. Evaluate effectiveness of antimicrobial prophylaxis for tick transmitted B. burgdorferi infection.